TIDMAGY

Allergy Therapeutics PLC

04 November 2014

4 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Appointment of Dr Daphne Tsitoura as Head of Clinical Science

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10(th) November, reporting to Professor Tim Higgenbottam.

Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York.

Tim Higenbottam, R & D Director said:

"With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US."

-Ends-

For further information

 
 Allergy Therapeutics                         +44 (0) 1903 845 820 
 Manuel Llobet, Chief Executive Officer 
 Ian Postlethwaite, Finance Director 
 www.allergytherapeutics.com 
 
 
 Peel Hunt LLP                                +44 (0) 20 7418 8900 
 James Steel / Clare Terlouw 
 
 
 FTI Consulting                               +44 (0) 20 3727 1000 
 Simon Conway / Victoria Foster Mitchell / 
  Mo Noonan 
 

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with revenue of GBP42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXFDEFELFFF

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Allergy Therapeutics Charts.